Financial Data and Key Metrics Changes - In Q4 2024, net sales reached $748.8 million, reflecting a 3.3% organic sales growth [24] - Adjusted operating profit margin was 21.7%, consistent with the prior year [26] - Adjusted diluted EPS declined by 0.5% for Q4 [26] Business Line Data and Key Metrics Changes - Proprietary product organic revenues decreased by 4.5% in Q4, primarily due to destocking [12] - High-value products (HVP) accounted for approximately 74% of Q4 proprietary product sales, generating mid-single-digit growth [25] - Contract manufacturing segment declined by low single digits [26] Market Data and Key Metrics Changes - Biologics market experienced high single-digit organic net sales growth, driven by self-injection device platforms [25] - Pharma saw mid-single-digit organic net sales growth, while generics faced a mid-single-digit organic net sales decline [25] Company Strategy and Development Direction - The company capitalized on opportunities in the fast-growing GLP-1 market and reduced manufacturing lead times [10] - Strategic investments were made in additional HVP capacity to drive incremental growth [10] - The company expects HPP component revenues to grow mid to high single digits in 2025, driven by the biologics market [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to organic growth, driven by the strength of the HPP components business [23] - The company anticipates 2025 will be an important year for positioning for future success [42] - Management noted that destocking impacts are expected to abate, leading to more normalized ordering patterns [68] Other Important Information - The company returned over $560 million to shareholders through share repurchase programs in 2024 [10] - Operating cash flow was $653.4 million in 2024, a decline of $123.1 million from the previous year [30] - Full-year 2025 net sales guidance is expected to be between $2.875 billion and $2.905 billion [32] Q&A Session Summary Question: EPS guidance for 2025 seems below expectations; can you clarify? - Management acknowledged that many impacts are affecting 2025, particularly in drug delivery devices, but expects improvements over time [50][51] Question: Can you elaborate on the contract manufacturing issue? - Management confirmed the decision to exit certain contracts was based on financial metrics, and they are looking to replace that business with higher-margin opportunities [56][58] Question: What is the outlook for proprietary products? - Management remains optimistic about HPP components and expects growth driven by biologics and GLP-1s [65][66] Question: Can you provide details on the GLP-1 market growth? - Management indicated that GLP-1s represent about 10% of overall business, with significant growth expected in proprietary elastomers [93] Question: What are the specific investments in SG&A and R&D? - Management stated that investments in SG&A and R&D are aimed at supporting growth initiatives and improving profitability [137]

Core Viewpoint - West Pharmaceutical Services reported quarterly earnings of $1.82 per share, exceeding the Zacks Consensus Estimate of $1.75 per share, although down from $1.83 per share a year ago, indicating a 4% earnings surprise [1] Financial Performance - The company achieved revenues of $748.8 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.25%, compared to $732 million in the same quarter last year [2] - Over the last four quarters, West Pharmaceutical has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance and Outlook - West Pharmaceutical shares have declined approximately 1.6% since the beginning of the year, while the S&P 500 has gained 2.9% [3] - The company's current consensus EPS estimate for the upcoming quarter is $1.63 on revenues of $715.32 million, and for the current fiscal year, it is $7.44 on revenues of $3.03 billion [7] Industry Context - The Medical - Dental Supplies industry, to which West Pharmaceutical belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, which may impact stock performance [8]

Sales Performance - Fourth-quarter 2024 net sales increased to $748.8 million, a 2.3% increase year-over-year, with organic net sales growth of 3.3%[6] - Full-year 2024 net sales were $2.893 billion, a decline of 1.9%, while organic net sales declined by 1.5%[9] - Fourth-quarter 2024 net sales for the Proprietary Products segment increased to $613.9 million, with organic net sales growth of 4.5%[3] - For the three months ended December 31, 2024, consolidated total net sales were $748.8 million, a 2.4% increase from $732.0 million in the same period of 2023[21] - Organic net sales for the three months ended December 31, 2024, were $756.0 million, reflecting a positive impact from currency translation rates[25] Earnings Per Share (EPS) - Fourth-quarter 2024 reported-diluted EPS was $1.78, a decline of 2.7%, and adjusted-diluted EPS was $1.82, a decline of 0.5%[6] - Full-year 2024 adjusted-diluted EPS was $6.75, a decline of 16.5% compared to the previous year[9] - Reported diluted EPS for the twelve months ended December 31, 2024, was $6.69, with guidance for 2025 projected between $5.97 and $6.17, indicating a potential decrease of 10.8% to 7.8%[26] - Full-year 2025 adjusted-diluted EPS is expected to be in the range of $6.00 to $6.20, including an estimated headwind of approximately $0.23 from foreign currency exchange rates[11] Cash Flow and Capital Expenditures - Operating cash flow for full-year 2024 was $653.4 million, a decline of 15.9%, while free cash flow decreased by 33.3% to $276.4 million[10] - Operating cash flow for the twelve months ended December 31, 2024, was $653.4 million, down from $776.5 million in 2023[29] - Capital expenditures for full-year 2025 are expected to be $275 million, supporting capacity expansions and investments in Contract Manufacturing facilities[11] - Capital expenditures for the twelve months ended December 31, 2024, were $377.0 million, compared to $362.0 million in 2023[29] Profitability Metrics - Gross profit for the twelve months ended December 31, 2024, was $998.5 million, down 11.5% from $1,129.2 million in 2023, resulting in a gross profit margin of 34.5% compared to 38.3%[21] - Adjusted operating profit for the three months ended December 31, 2024, was $162.8 million, reflecting a 1.8% increase from $159.9 million in the same period of 2023[22] Restructuring and Working Capital - The company recorded a restructuring expense of $3.0 million for the three months ended December 31, 2024, related to optimizing its legal structure[23] - Working capital as of December 31, 2024, was $987.7 million, down from $1,264.6 million in 2023[31] Market Performance - The Biologics market unit experienced high-single digit organic net sales growth, driven by self-injection device platforms[4]

- Conference Call Scheduled for 9 a.m. EDT Today -EXTON, Pa., Feb. 13, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance.Fourth-Quarter Summary (comparisons to prior-year period) & Full-Year 2025 Guidance Fourth-quarter 2024 net sales of $748.8 million increased 2.3%; organic net sales grew 3.3%. Fourth-quarter 2024 reported-diluted EPS of $1.78 declined 2.7%; fourth-quart ...

West Pharmaceutical Services (WST) is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 22.52%. WST’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.04%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesCurrently, the Zacks Consensus Estimate for revenues is pegged at $739.6 million, indicating grow ...

EXTON, Pa., Jan. 30, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST),  global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.The live webcast will be made available via the Company's Investor Relations website or ...

EXTON, Pa., Jan. 28, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2025 dividend of $0.21 per share. The dividend will be paid on February 11, 2025, to shareholders of record as of February 7, 2025.About West  West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. ...

EXTON, Pa., Jan. 22, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the introduction of Daikyo PLASCAP® Ready-to-Use Validated (RUV) closures in a new nested format available in multiple configurations at this year's Pharmapack event in Paris, France.  This marks West's latest product offering supporting the needs of advanced therapies, one of the fastest growing areas, driven by continued innov ...

EXTON, Pa., Jan. 6, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that Cindy Reiss-Clark, Sr. VP and Chief Commercial Officer; Chad Winters, VP of Finance and Chief Accounting Officer; and John Sweeney, VP of Investor Relations, will present at the CJS 25th Annual "New Ideas for the New Year" Virtual Investor Conference on January 14, 2025 at 10:15 a.m. ET.  A live audio webcast will be availab ...

Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estim ...